As one of the first pharmaceutical companies to respond to the emerging novel coronavirus (COVID-19) crisis, in late January, AbbVie donated a supply of Kaletra/Aluvia (lopinavir/ritonavir) to the Chinese health authorities for use as an experimental treatment option.
We are committed to making a meaningful contribution to efforts to combat this global public health crisis and continue to address urgent supply needs in several countries impacted by the outbreak. Our company is also working closely with the World Health Organization (WHO) and global health authorities to respond to the needs of patients impacted by COVID-19. Specifically, we have taken action through the provision of Kaletra/Aluvia as an experimental option for treatment of COVID-19, and through coordination with WHO, US NIH, and our industry partners. Our company is also exploring a potential research collaboration with the Innovative Medicines Initiative (IMI), which is exploring multiple potential COVID-19 treatment options.